Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 2,700 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 2,700 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $20.04, for a total transaction of $54,108.00. Following the completion of the transaction, the insider now owns 160,888 shares of the company’s stock, valued at approximately $3,224,195.52. The trade was a 1.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Natarajan Sethuraman also recently made the following trade(s):

• On Monday, November 11th, Natarajan Sethuraman sold 1,409 shares of Entrada Therapeutics stock. The shares were sold at an average price of $20.01, for a total transaction of $28,194.09.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.09, for a total value of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.24, for a total value of $9,144.00.

Entrada Therapeutics Price Performance

TRDA opened at $17.85 on Friday. Entrada Therapeutics, Inc. has a 12 month low of $10.75 and a 12 month high of $20.49. The stock has a market capitalization of $667.95 million, a P/E ratio of 11.23 and a beta of -0.26. The business has a 50 day simple moving average of $16.76 and a 200-day simple moving average of $15.92.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $94.69 million during the quarter, compared to the consensus estimate of $55.00 million. Research analysts anticipate that Entrada Therapeutics, Inc. will post 1.07 EPS for the current year.

Institutional Trading of Entrada Therapeutics

A number of institutional investors have recently bought and sold shares of TRDA. Renaissance Technologies LLC acquired a new position in shares of Entrada Therapeutics during the 2nd quarter worth $636,000. The Manufacturers Life Insurance Company raised its position in Entrada Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock worth $814,000 after acquiring an additional 2,146 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Entrada Therapeutics in the first quarter valued at about $79,000. Vanguard Group Inc. grew its position in shares of Entrada Therapeutics by 1.3% in the first quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after purchasing an additional 13,742 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Entrada Therapeutics by 427.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after purchasing an additional 11,965 shares in the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. HC Wainwright boosted their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Oppenheimer boosted their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 6th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.